Elevated plasma levels of apolipoprotein B (apo B) and low density lipoprotein (LDL) are associated with a higher risk for atherosclerotic coronary heart disease (CHD), a leading cause of mortality in the industrialized world. Elevated plasma apo B levels and overproduction of apo B are also major characteristics of familial combined hyperlipidemia (FCHL), a prevalent disorder in the general population. The genetic basis of this prevalent disease is heterogeneous and unknown. Genes that regulate plasma apo B levels are logical candidates for genes which contribute to the FCHL phenotype. Apo B is required for the secretion of very low density lipoproteins (VLDL) from the liver and is the mandatory protein constituent of both plasma VLDL and LDL. Plasma apo B levels are controlled, in part, by secretion rates of apo B-containing lipoprotein particles. Using the human apo B transgenic mouse model (HuBTg), we have shown that HuBTg mice of C57BL/6 (B6) and 129/Sv (129) background differ in their plasma apo B levels mainly due to hepatic apo B secretion rates via post-transcriptional regulation. Further genetic studies of two mouse strains identified two novel quantitative trait loci (QTL) on chromosomes 6 and 4 which have major effects on plasma apo B levels. These genes are designated Apo B regulatory genes (Abrg). Our fine-mapping analyses have localized the Abrgl to an interval of approximately 2.9 Mb on chromosome 6 and the Abrg2 to a 12-cM interval on chromosome 4. The goals of the current proposal are to identify and characterize the Abrgl gene on chromosome 6.
The specific aims are: 1. Positional cloning of the Abrgl on chromosome 6 that regulates plasma apo B levels. Several parallel approaches will be taken to identify candidate genes for the Abrgl. These approaches include RT-PCR, quantitative real-time PCR assays, and DNA sequencing analysis. Studies will also be designed to determine the effects of allelic variations of expression variants on transcription. 2. Characterization of the Abrg genes in congenic mice and functional studies of the Abrgl candidate genes. We will perform functional tests on candidate variant genes, including the Copsla gene (an expression variant), by over expression studies in vitro and in vivo. The best candidate for the Abrgl gene, either Cops7a or another gene to be identified, will then be verified via knock-in and/or knock-out gene-targeting techniques. Studies will be designed to characterize the functional roles of the Abrgl gene. Overall, the gene identified will be a novel regulator affecting the pathways involved in the assembly and secretion of apo B containing lipoproteins. As a regulator of apo B secretion rates, this novel gene will be a strong candidate for one of the genes causative for overproduction of apo B in subsets of FCHL patients. It will also be a potential target for drug discovery and pharmacological intervention in hyperlipidemic patients in the general population. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL062583-06
Application #
7114387
Study Section
Integrative Nutrition and Metabolic Processes Study Section (INMP)
Program Officer
Srinivas, Pothur R
Project Start
2000-04-01
Project End
2009-05-31
Budget Start
2006-06-01
Budget End
2007-05-31
Support Year
6
Fiscal Year
2006
Total Cost
$353,738
Indirect Cost
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Liu, Li; Yu, Shuiqing; Khan, Raffay S et al. (2011) DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle. J Lipid Res 52:732-44
Reid, Brendan N; Ables, Gene P; Otlivanchik, Oleg A et al. (2008) Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis. J Biol Chem 283:13087-99
Goldberg, Ira J; Hu, Yunying; Noh, Hye-Lim et al. (2008) Decreased lipoprotein clearance is responsible for increased cholesterol in LDL receptor knockout mice with streptozotocin-induced diabetes. Diabetes 57:1674-82
Son, Ni-Huiping; Park, Tae-Sik; Yamashita, Haruyo et al. (2007) Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest 117:2791-801
Zhang, Yuan-Li; Hernandez-Ono, Antonio; Siri, Patty et al. (2006) Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J Biol Chem 281:37603-15
Devlin, Cecilia M; Lee, Sung-Joon; Kuriakose, George et al. (2005) An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo. Arterioscler Thromb Vasc Biol 25:1704-10
Goldberg, Ira J; Isaacs, Aaron; Sehayek, Ephraim et al. (2004) Effects of streptozotocin-induced diabetes in apolipoprotein AI deficient mice. Atherosclerosis 172:47-53
Zhang, Yuan-Li; Hernandez-Ono, Antonio; Ko, Carol et al. (2004) Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids. I. Differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles. J Biol Chem 279:19362-74
Ko, Carol; O'Rourke, Shawn M; Huang, Li-Shin (2003) A fish oil diet produces different degrees of suppression of apoB and triglyceride secretion in human apoB transgenic mouse strains. J Lipid Res 44:1946-55
Glover, L; Culligan, K; Cala, S et al. (2001) Calsequestrin binds to monomeric and complexed forms of key calcium-handling proteins in native sarcoplasmic reticulum membranes from rabbit skeletal muscle. Biochim Biophys Acta 1515:120-32

Showing the most recent 10 out of 11 publications